Union

Hikvision becomes the Official Sponsor of the Hangzhou 2022 Asian Games

Retrieved on: 
Wednesday, January 19, 2022 - 10:00pm

HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ --At a signing ceremony held on January 18 in Hangzhou, Hikvision announced that it becomes the Official Intelligent IoT & Big Data Sponsor of the 19th Asian Games Hangzhou 2022 and the 4th Asian Paralympic Games.

Key Points: 
  • HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ --At a signing ceremony held on January 18 in Hangzhou, Hikvision announced that it becomes the Official Intelligent IoT & Big Data Sponsor of the 19th Asian Games Hangzhou 2022 and the 4th Asian Paralympic Games.
  • These offerings will truly contribute to the "Smart Asian Games".
  • Throughout this partnership, Hikvision will also actively participate in the big charity campaign "2022 Asian Games Aspirations", and jointly promote sports charity with the Organizing Committee of Hangzhou Asian Games.
  • Committed to the utmost quality and safety of its products, Hikvision encourages partners to take advantage of the many cybersecurity resources Hikvision offers, including the Hikvision Cybersecurity Centre.

Enviva Announces MOU With U.S. Customer, Provides Updates to Business and Sales Pipeline, and Accelerates Capacity Expansions

Retrieved on: 
Wednesday, January 19, 2022 - 9:33pm

Under the MOU, the customers refining process will convert Envivas woody biomass into a drop-in replacement for crude oil used for producing aviation fuel.

Key Points: 
  • Under the MOU, the customers refining process will convert Envivas woody biomass into a drop-in replacement for crude oil used for producing aviation fuel.
  • This contracted revenue backlog is complemented by a customer sales pipeline exceeding $40 billion, which includes contracts in various stages of negotiation.
  • Over the next 12 months, we expect to progress negotiations and convert several sales pipeline opportunities into binding contracts, including MOUs.
  • Consistent with prior updates, we expect Envivas previously announced Multi-Plant Expansions to be completed by year-end 2022.

Enviva Announces Public Offering of Common Stock

Retrieved on: 
Wednesday, January 19, 2022 - 9:38pm

Enviva Inc. (NYSE: EVA) is the worlds largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets.

Key Points: 
  • Enviva Inc. (NYSE: EVA) is the worlds largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets.
  • Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi.
  • Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with customers in the United Kingdom, the European Union, and Japan.
  • Enviva cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Enviva.

Union Bankshares Announces Earnings for the year ended December 31, 2021 and Declares 6.1% Increase in Quarterly Dividend

Retrieved on: 
Wednesday, January 19, 2022 - 7:42pm

These changes resulted in net interest income of $9.2 million, an increase of $1.1 million, or 13.6%, quarter over quarter.

Key Points: 
  • These changes resulted in net interest income of $9.2 million, an increase of $1.1 million, or 13.6%, quarter over quarter.
  • Noninterest income was $3.0 million for the three months ended December 31, 2021 compared to $5.0 million for the same period in 2020.
  • A larger earning asset base and a $1.9 million increase in PPP fee income contributed to the increase in interest income.
  • Interest expense was $3.6 million for the year ended December 31, 2021 compared to $5.1 million for the year ended December 31, 2020.

DGAP-News: Mainz Biomed Engages DCN Dx to Support Clinical Study Evaluating Novel mRNA Biomarkers for Potential Integration into ColoAlert

Retrieved on: 
Wednesday, January 19, 2022 - 8:23pm

Under the terms of the engagement, DCN Dx will be responsible for the selection of additional clinical research organizations (CRO) and assist Mainz's management with the development of robust study protocols and associated clinical processes.

Key Points: 
  • Under the terms of the engagement, DCN Dx will be responsible for the selection of additional clinical research organizations (CRO) and assist Mainz's management with the development of robust study protocols and associated clinical processes.
  • Emily brings to the project over 20 years of clinical research experience as a scientist and executive.
  • Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates.
  • DCN Dx provides end-to-end support for rapid diagnostic test development and production in an array of applications.

DGAP-News: CryptoSimple On Track to Launch Service in European Union in 2022

Retrieved on: 
Wednesday, January 19, 2022 - 8:22pm

MARSEILLE, FRANCE / ACCESSWIRE / January 19, 2022 / CryptoSimple , the financial advisor service for Cryptocurrency assets, is pleased to announce that they are on track to launch in the European Union in 2022.

Key Points: 
  • MARSEILLE, FRANCE / ACCESSWIRE / January 19, 2022 / CryptoSimple , the financial advisor service for Cryptocurrency assets, is pleased to announce that they are on track to launch in the European Union in 2022.
  • Founded in March of 2021, CryptoSimple saw the opportunity for traditional investors to participate in Decentralized Finance (DeFi).
  • As of January 2022, over $100 Billion worth of assets are locked in DeFi through apps like CryptoSimple.
  • CryptoSimple CEO Franois Julien is excited about their impending launch, "With CryptoSimple we aim to simplify the process of investing in cryptocurrencies.

ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis

Retrieved on: 
Wednesday, January 19, 2022 - 1:30pm

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021. TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • This approval follows the U.S. Food and Drug Administration (FDA) approval of TAVNEOS in October 2021.
  • TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • ChemoCentryx is also developing TAVNEOS for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS) and Lupus Nephritis (LN).
  • In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis.

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

Retrieved on: 
Wednesday, January 19, 2022 - 12:00pm

SAN DIEGO and SUZHOU, China, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biotech company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the appointment of David Gandara, M.D., to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Gandara, Professor Emeritus and Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center (UCDCCC), brings deep knowledge and understanding to the immuno-oncology field, and he is recognized for his translational research and clinical work in cancer drug and biomarker development.

Key Points: 
  • Dr. Gandara commented, "I am delighted to join Adagenes SAB at such an exciting time in the company's evolution.
  • Together we look forward to maximizing the potential of our platform to transform immunotherapy for cancer patients across the world.
  • For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/
    Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotech company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
  • Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

Transaction in Own Shares

Retrieved on: 
Wednesday, January 19, 2022 - 5:29pm

These share purchases form part of the Company's share buy-back arrangement previously announced on 02 December 2021.

Key Points: 
  • These share purchases form part of the Company's share buy-back arrangement previously announced on 02 December 2021.
  • In respect of this arrangement, BNP Paribas Exane will make trading decisions in relation to the Companys securities independently of the Company for a period from 02 December 2021 up to and including 28 January 2022.
  • In accordance with EU MAR and UK MAR, a full breakdown of the individual trades made by BNP Paribas Exane on behalf of the Company as a part of the buy-back arrangement is detailed below.
  • LEI number of Royal Dutch Shell plc: 21380068P1DRHMJ8KU70

ASML reports €18.6 billion net sales and €5.9 billion net income in 2021

Retrieved on: 
Wednesday, January 19, 2022 - 6:00am

A complete summary of US GAAP Consolidated Statements of Operations is published on www.asml.com

Key Points: 
  • A complete summary of US GAAP Consolidated Statements of Operations is published on www.asml.com
    "Our fourth-quarter net sales came in at 5.0 billion which is within our guidance.
  • Our fourth-quarter net bookings came in at 7.1 billion, including 2.6 billion from 0.33 NA and 0.55 NA EUV systems.
  • "The total net sales for the year was 18.6 billion, including 6.3 billion from 42 EUV systems.
  • "ASML expects first-quarter net sales between 3.3 billion and 3.5 billion with a gross margin of around 49%.